Rate limiting step in porphyrine synthesis –
**Core Concept:**
The question is about the rate-limiting step in porphyrin synthesis, which is a process involved in the production of heme, a molecule containing iron that plays a crucial role in the transport of oxygen within red blood cells and the regulation of certain enzymatic reactions in the body. Porphyrins are the precursors of heme and are synthesized in the liver.
**Why the Correct Answer is Right:**
The correct answer is **D**. The rate-limiting step in porphyrin synthesis occurs in the **uroporphyrinogen III decarboxylase (UROD)** enzyme, specifically in the conversion of uroporphyrinogen III to coproporphyrinogen III. This step is rate-limiting because it is the last step in the heme synthesis pathway, and any delay or impairment in this process can lead to the accumulation of porphyrins in the body, resulting in porphyria.
**Why Each Wrong Option is Incorrect:**
Option A (aminolaevulinic acid dehydratase) is incorrect because it is the enzyme responsible for the second step in the pathway, converting aminolaevulinic acid to porphobilinogen. This step is not rate-limiting, as multiple other enzymes are involved in the subsequent reactions.
Option B (porphobilinogen deaminase) is incorrect because it is the enzyme responsible for the fourth step in the pathway, converting porphobilinogen to uroporphyrinogen III. This step is not rate-limiting, as multiple other enzymes are involved in the subsequent reactions.
Option C (coproporphyrinogen oxidase) is incorrect because it is the enzyme responsible for the fifth step in the pathway, converting coproporphyrinogen III to copro IX. This step is not rate-limiting, as multiple other enzymes are involved in the final steps of the pathway.
**Clinical Pearl:**
Understanding the rate-limiting steps in heme synthesis is essential for diagnosing and managing patients with hereditary disorders of heme synthesis, such as porphyrias. These disorders are characterized by an accumulation of porphyrins in the body, leading to neurological, gastrointestinal, and cutaneous symptoms. Early diagnosis is crucial for proper management and treatment, including porphyrin chelation therapy.